ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 561,13
1,09%
Dow Jones
39 169,52
0,13%
DAX
18 290,66
0,31%
Brent Oil
86,685
0,18%
Bitcoin
63 143,20
0,47%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Prevail Therapeutics Inc (PRVL)

  7. Prevail Therapeutics Inc (PRVL) Actualités

PRVL

Prevail Therapeutics (PRVL)

Prevail Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRVL
DateHeureSourceTitreSymboleSociété
16/02/202122h43Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PRVLPrevail Therapeutics Inc
01/02/202112h41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:PRVLPrevail Therapeutics Inc
29/01/202122h16Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PRVLPrevail Therapeutics Inc
29/01/202112h13Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PRVLPrevail Therapeutics Inc
27/01/202112h12Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PRVLPrevail Therapeutics Inc
26/01/202123h20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202122h39Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202115h26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202115h03Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202114h55PR Newswire (US)Lilly Completes Acquisition of Prevail TherapeuticsNASDAQ:PRVLPrevail Therapeutics Inc
20/01/202113h01Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:PRVLPrevail Therapeutics Inc
20/01/202112h44Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:PRVLPrevail Therapeutics Inc
22/12/202014h50Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:PRVLPrevail Therapeutics Inc
22/12/202014h34Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:PRVLPrevail Therapeutics Inc
22/12/202013h08Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:PRVLPrevail Therapeutics Inc
15/12/202023h05Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:PRVLPrevail Therapeutics Inc
15/12/202013h35Dow Jones NewsLilly Raises 2020 Guidance, Sets 2021 OutlookNASDAQ:PRVLPrevail Therapeutics Inc
15/12/202013h17Dow Jones NewsLilly to Buy Prevail Therapeutics for Up to $1.04 BillionNASDAQ:PRVLPrevail Therapeutics Inc
15/12/202012h39Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:PRVLPrevail Therapeutics Inc
15/12/202012h15PR Newswire (US)Lilly Announces Agreement to Acquire Prevail TherapeuticsNASDAQ:PRVLPrevail Therapeutics Inc
11/12/202013h00GlobeNewswire Inc.Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of...NASDAQ:PRVLPrevail Therapeutics Inc
30/11/202013h00GlobeNewswire Inc.Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal DementiaNASDAQ:PRVLPrevail Therapeutics Inc
19/11/202001h01GlobeNewswire Inc.Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001NASDAQ:PRVLPrevail Therapeutics Inc
13/11/202013h21Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PRVLPrevail Therapeutics Inc
13/11/202013h00GlobeNewswire Inc.Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business HighlightsNASDAQ:PRVLPrevail Therapeutics Inc
10/11/202013h00GlobeNewswire Inc.Prevail Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:PRVLPrevail Therapeutics Inc
02/11/202013h00GlobeNewswire Inc.Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEONASDAQ:PRVLPrevail Therapeutics Inc
27/10/202012h00GlobeNewswire Inc.Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher DiseaseNASDAQ:PRVLPrevail Therapeutics Inc
18/09/202021h04GlobeNewswire Inc.Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech SummitNASDAQ:PRVLPrevail Therapeutics Inc
11/09/202014h29Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PRVLPrevail Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PRVL

Dernières Valeurs Consultées

NASDAQ
ZAEMTX
Ares Special Situations ...
NASDAQ
ZABSJX
Aether Real Assets Coinv...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés